Synthesis and electrophysiological characterization of cyclic morphiceptin analogues

Biochemical Pharmacology

Volumn 67, Issue 10, 2004, Pages 1887-1895

  Pil, Joost ^a   Van Der Veken, Pieter ^b   Bal, Gunther ^b   Augustyns, Koen ^b   Haemers, Achiel ^b   Tytgat, Jan ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

32 GIRK1 GIRK2; benzotriazole 1 yloxytris(dimethylamino) phosphoniumhexafluorophosphate; Boc; BOP; fluoren 9 ylmethylsuccinimidyl carbonate; Fmoc; G protein coupled inwardly rectifying potassium channel; hDOR; t butoxycarbonyl

Indexed keywords

ANTIDIARRHEAL AGENT; DELTA OPIATE RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; INWARDLY RECTIFYING POTASSIUM CHANNEL; KAPPA OPIATE RECEPTOR; MORPHICEPTIN DERIVATIVE; MU OPIATE RECEPTOR;

ANIMAL CELL; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CYCLIZATION; DRUG DESIGN; DRUG POTENCY; ELECTROPHYSIOLOGY; MICROELECTRODE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR INTRINSIC ACTIVITY; VOLTAGE CLAMP; WILD TYPE; XENOPUS LAEVIS;

ANIMALS; ELECTROPHYSIOLOGY; ENDORPHINS; G PROTEIN-COUPLED INWARDLY-RECTIFYING POTASSIUM CHANNELS; OOCYTES; OPIOID PEPTIDES; PEPTIDES, CYCLIC; POTASSIUM CHANNELS; POTASSIUM CHANNELS, INWARDLY RECTIFYING; RECEPTORS, OPIOID, MU; XENOPUS LAEVIS;

EID: 2342518210     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2004.02.011     Document Type: Article

References (27)

1. Raynor K., Kong H., Chen Y., Yasuda K., Yu L., Bell G.I., et al. Pharmacological characterization of the cloned kappa-, delta-, and mu- opioid receptors. Mol. Pharmacol. 45(2):1994;330-334
2. Zadina J., Hackler L., Ge L., Kastin A. A potent and selective endogenous agonist for the mu-opiate receptor. Nature. 386(6624):1997;499-502
3. Chang K.J., Lillian A., Hazum E., Cuatrecasas P., Chang J.K. Morphiceptin (NH4-tyr-pro-phe-pre-COHN2): a potent and specific agonist for morphine (mu) receptors. Science. 212(4490):1981;75-77
4. Shook J., Lemcke P., Gehrig C., Hruby V., Burks T. Antidiarrheal properties of supraspinal mu and delta and peripheral mu, delta and kappa opioid receptors: inhibition of diarrhea without constipation. J. Pharmacol. Exp. Ther. 249(1):1989;83-90
5. Hatzoglou A., Bakogeorgou E., Papakonstanti E., Stournaras C., Emmanouel D., Castanas E. Identification and characterization of opioid and somatostatin binding sites in the opossum kidney (OK) cell line and their effect on growth. J. Cell Biochem. 63(4):1996;410-421
6. Kampa M., Bakogeorgou E., Hatzoglou A., Damianaki A., Martin P., Castanas E. Opioid alkaloids and casomorphin peptides decrease the proliferation of prostatic cancer cell lines (LNCaP, PC3 and DU145) through a partial interaction with opioid receptors. Eur. J. Pharmacol. 335(2/3):1997;255-265
7. Janecka A., Fichna J., Wiercioch R., Mirowski M. Synthesis of novel morphiceptin analogues modified in position 3 and their binding to μ-opioid receptors in experimental mammary adenocarcinoma. Bioorg. Med. Chem. 11(18):2003;3855-3860
8. Chang K., Wei E., Killian A., Chang J. Potent morphiceptin analogs: structure activity relationships and morphine-like activities. J. Pharmacol Exp. Ther. 227(2):1983;403-408
9. Janecka A., Fichna J., Mirowski M., Janecki T. Structure-activity relationship, conformation and pharmacology studies of morphiceptin analogues-selective mu-opioid receptor ligands. Mini Rev. Med. Chem. 2(6):2002;565-572
10. Yamazaki T., Ro S., Goodman M., Chung N., Schiller P. A topochemical approach to explain morphiceptin bioactivity. J. Med. Chem. 36(6):1993;708-719
11. Stewart J. Optimization of parameters for semiemperical methods. 1. Method. J. Comp. Chem. 10(2):1989;209-220
12. Stewart J. MOPAC: a semiempirical molecular orbital program. J. Comput. Aided Mol. Des. 4(1):1990;1-105
13. Kofuji P., Davidson N., Lester H.A. Evidence that neuronal G-protein-gated inwardly rectifying K+ channels are activated by G beta gamma subunits and function as heteromultimers. Proc. Natl. Acad. Sci. USA. 92(14):1995;6542-6546
14. Doupnik C.A., Davidson N., Lester H.A., Kofuji P. RGS proteins reconstitute the rapid gating kinetics of betagamma- activated inwardly rectifying K+ channels. Proc. Natl. Acad. Sci. USA. 94(19):1997;10461-10466
15. Ulens C., Daenens P., Tytgat J. Changes in GIRK1/GIRK2 deactivation kinetics and basal activity in the presence and absence of RGS4. Life Sci. 67(19):2000;2305-2317
16. Pil J., Tytgat J. Serine 329 of the μ-opioid receptor interacts differently with agonists. J. Pharmacol. Exp. Ther. 304(3):2003;924-930
17. Ulens C., Van Boven M., Daenens P., Tytgat J. Interaction of p-fluorofentanyl on cloned human opioid receptors and exploration of the role of Trp-318 and His-319 in mu-opioid receptor selectivity. J. Pharmacol. Exp. Ther. 294(3):2000;1024-1033
18. Pil J., Tytgat J. The role of the hydrophilic Asn230 residue of the μ-opioid receptor in the potency of various opioid agonists. Br. J. Pharmacol. 134(3):2001;496-506
19. Kobayashi T., Ikeda K., Ichikawa T., Abe S., Togashi S., Kumanishi T. Molecular cloning of a mouse G-protein-activated K+ channel (mGIRK1) and distinct distributions of three GIRK (GIRK1, 2 and 3) mRNAs in mouse brain. Biochem. Biophys. Res. Commun. 208(3):1995;1166-1173
20. Krieg P.A., Melton D.A. Functional messenger RNAs are produced by SP6 in vitro transcription of cloned cDNAs. Nucleic Acids Res. 12(18):1984;7057-7070
21. Liman E.R., Tytgat J., Hess P. Subunit stoichiometry of a mammalian K+ channel determined by construction of multimeric cDNAs. Neuron. 9(5):1992;861-871
22. Lambeir A.-M., Proost P., Durinx C., Bal G., Senten K., Augustyns K., et al. Kinetic investigation of chemokine truncation by CD26/dipeptidyl peptidase IV reveals a striking selectivity within the chemokine family. J. Biol. Chem. 276(32):2001;29839-29845
23. Keller M., Boissard C., Patiny L., Chung N., Lemieux C., Mutter M., et al. Pseudoproline-containing analogues of morphiceptin and endomorphin-2: evidence for a cis Tyr-Pro amide bond in the bioactive conformation. J. Med. Chem. 44(23):2001;3896-3903
24. Paterlini M.G., Avitabile F., Ostrowski B.G., Ferguson D.M., Portoghese P.S. Stereochemical requirements for receptor recognition of the mu-opioid peptide endomorphin-1. Biophys. J. 78(2):2000;590-599
25. Okada Y., Tsuda Y., Bryant S., Lazarus L. Endomorphins and related opioid peptides. Vitam. Horm. 65:2002;257-279
26. Tiruppathi C., Miyamoto Y., Ganapathy V., Leibach F. Genetic evidence for role of DPP IV in intestinal hydrolysis and assimilation of prolyl peptides. Am. J. Physiol. 265(1 Pt 1):1993;G81-G89
27. Hau V., Huber J., Campos C., Lipkowski A., Misicka A., Davis T. Effect of guanidino modification and proline substitution on the in vitro stability and blood-brain barrier permeability of endomorphin II. J. Pharm. Sci. 91(10):2002;2140-2149